The results showed that SIRT1, MAPK3, NFE2L2, CDKN1A, CDKN2A, CDH1, ATG7, CD44, and GSK3B exhibited significantly high expression in AML samples. This evidence concerns the gene CD44 and acute myeloid leukemia.